Steven L. Wagner, | 2020

Comprehensive Analyses of Chronic Efficacy Studies with GSM 776890 for Submission of the Pre-IND Brochure to the FDA Prior to Pre-IND Meeting and IND Filing for the SAD/MAD Phase I Safety/Toxicity and Ultimately for Phase II and Phase III Efficacy Clinical Trials to Support the NDA

Nanda Kumar Navalpur Shanmugam, Deepak Vijaya Kumar, Rudolph Tanzi, William Eimer, | 2020

Microbes and Alzheimer’s Disease: Metagenomics on Saliva, CSF, Blood and Brain

Jean-Pierre Roussarie, | 2020

Regulation by Apolipoprotein E of Selective Neuronal Vulnerability to Alzheimer’s Disease

Guojun Bu, | 2020

Counteracting Pathogenic Events in Alzheimer’s Disease with Peripheral or Central Apolipoprotein E

Randall J. Bateman, | 2020

Assessing the Added Diagnostic Value of Peripheral Apolipoprotein E Protein Levels in Current Blood-Based Biomarker Assays for Central Nervous System Amyloidosis

Giuseppina Tesco, | 2020

In Vivo Characterization of a Loss-of-Function GGA3 Rare Variant Associated with Alzheimer’s Disease

Krista L. Moulder, | 2020

Characterization of Alzheimer’s Disease Molecular Biomarker Profiles Throughout the Pathobiological Continuum

Takahisa Kanekiyo, Guojun Bu, | 2020

ABCA7 Loss of Function in Aging and Alzheimer’s Disease

Ali Ezzati, Richard Lipton, | 2020

Improving Alzheimer’s Disease Clinical Trials’ Design by Machine Learning Models

Berislav Zlokovic, | 2019

Molecular Signatures of APOE-Mediated Blood-Brain Barrier Dysfunction Causing Neuronal and Synaptic Dysfunction

Shirley Wray,

An Innovative Study of the Pupil Light Reflex in Alzheimer’s Disease

Howard L. Weiner, Laura Cox, | 2019

Targeting the Microbiome and Microglia in Alzheimer’s Disease